Pancreatic Ductal Adenocarcinoma and Nutrition: Exploring the Role of Diet and Gut Health.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
21 Oct 2023
Historique:
received: 16 09 2023
revised: 18 10 2023
accepted: 20 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

The incidence of pancreatic cancer is increasing worldwide. The most common form is represented by pancreatic ductal adenocarcinoma (PDAC) which has been shown to be linked to chronic inflammation. Notably, the gut microbiota has emerged as a critical player in regulating immune responses and inflammation. Indeed, intestinal dysbiosis, characterized by an imbalance in the gut microbiota composition, can contribute to the initiation of chronic inflammation. Sterile chronic inflammation can occur, probably activated by the translocation of bacterial components, such as lipopolysaccharide (LPS), the major component of Gram-negative microbiota, with the consequent induction of innate mucosal immunity, through the activation of Toll-like receptors (TLRs). Furthermore, the interaction between LPS and TLRs could enhance cancer progression. Recent research has shed light on the pivotal role of nutrition, as a modifiable risk factor, in PDAC immunological processes, particularly focusing on the immuno-modulatory effects of the gut microbiota. Different dietary regimens, fiber intake, immunonutrients, and antioxidants have the potential to either exacerbate or mitigate chronic inflammation, thereby influencing the pathogenesis and natural history of PDAC. These dietary components may affect the gut microbiota composition and, consequently, the level of inflammation, either promoting or protecting against PDAC. In this review of reviews, we discuss the modulatory role of nutrition and the gut microbiota in PDAC's immunological processes to explore a translational therapeutic approach that could improve the survival and quality of life of these patients.

Identifiants

pubmed: 37892540
pii: nu15204465
doi: 10.3390/nu15204465
pmc: PMC10610120
pii:
doi:

Substances chimiques

Lipopolysaccharides 0
Toll-Like Receptors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Medicine (Baltimore). 2018 Mar;97(13):e0114
pubmed: 29595633
Medicina (Kaunas). 2022 Jul 22;58(8):
pubmed: 35893093
Nutrients. 2021 Dec 10;13(12):
pubmed: 34959977
Pancreatology. 2017 Nov - Dec;17(6):867-874
pubmed: 28935288
World J Gastroenterol. 2022 Dec 28;28(48):6827-6845
pubmed: 36632312
J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211068826
pubmed: 35018864
Gut. 2022 Jul;71(7):1359-1372
pubmed: 35260444
Cancer Manag Res. 2023 Jan 06;15:17-30
pubmed: 36643074
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764482
Nutrients. 2022 Oct 31;14(21):
pubmed: 36364832
Pancreas. 2021 May-Jun 01;50(5):657-666
pubmed: 34106574
Mediators Inflamm. 2018 Feb 1;2018:7946431
pubmed: 29563853
JAMA. 2021 Sep 7;326(9):851-862
pubmed: 34547082
Gastroenterology. 2019 May;156(7):2024-2040
pubmed: 30721664
Am J Clin Nutr. 2018 Mar 1;107(3):436-444
pubmed: 29566200
BMC Cancer. 2018 May 4;18(1):529
pubmed: 29728093
Nutr Cancer. 2019;71(3):375-384
pubmed: 30849232
Cancer Discov. 2023 Feb 6;13(2):278-297
pubmed: 36622087
Front Physiol. 2012 Jul 13;3:270
pubmed: 22969725
J Biol Regul Homeost Agents. 2010 Jul-Sep;24(3):239-49
pubmed: 20846472
Gastroenterology. 2013 Jun;144(6):1220-9
pubmed: 23622131
Public Health Nutr. 2021 Dec;24(18):6427-6435
pubmed: 33843543
Clin Gastroenterol Hepatol. 2013 Jun;11(6):719-30.e5
pubmed: 23200980
World J Gastroenterol. 2017 Mar 14;23(10):1899-1908
pubmed: 28348497
Cancers (Basel). 2022 Dec 02;14(23):
pubmed: 36497456
Int J Mol Sci. 2019 Jan 24;20(3):
pubmed: 30682772
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
PLoS One. 2016 May 12;11(5):e0154016
pubmed: 27170998
Int J Mol Sci. 2021 Nov 25;22(23):
pubmed: 34884547
J Acad Nutr Diet. 2018 Apr;118(4):555-567
pubmed: 28919082
NPJ Precis Oncol. 2023 Mar 8;7(1):26
pubmed: 36890302
World J Gastroenterol. 2014 Aug 28;20(32):11160-81
pubmed: 25170202
Cancers (Basel). 2022 Apr 28;14(9):
pubmed: 35565341
Mol Biol Rep. 2022 Nov;49(11):11037-11048
pubmed: 36097109
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Nutrients. 2021 Sep 15;13(9):
pubmed: 34579079
Oxid Med Cell Longev. 2021 Nov 3;2021:4393266
pubmed: 34777687
Biomolecules. 2022 Oct 17;12(10):
pubmed: 36291712
Acta Pharm Sin B. 2021 May;11(5):1148-1157
pubmed: 34094825
Int J Mol Sci. 2016 May 26;17(6):
pubmed: 27240340
Front Immunol. 2022 Apr 14;13:850093
pubmed: 35493517
Int J Environ Res Public Health. 2023 Jan 29;20(3):
pubmed: 36767770
Cancers (Basel). 2023 Apr 18;15(8):
pubmed: 37190281
Nutr Res. 2018 Apr;52:1-13
pubmed: 29764623
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5927-5945
pubmed: 37401330
Antioxidants (Basel). 2022 Jul 11;11(7):
pubmed: 35883840
Nutr Res. 2021 Apr;88:1-18
pubmed: 33607535
Cureus. 2022 Aug 29;14(8):e28543
pubmed: 36185865
Nature. 2020 Jan;577(7789):167-169
pubmed: 31911697
Microbiome. 2022 Jun 15;10(1):93
pubmed: 35701831
Diagnostics (Basel). 2021 Mar 20;11(3):
pubmed: 33804776
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Front Cell Infect Microbiol. 2022 Apr 06;12:872019
pubmed: 35463649
Expert Rev Anticancer Ther. 2018 Dec;18(12):1189-1203
pubmed: 30220238
Cancer Gene Ther. 2017 Mar;24(3):100-105
pubmed: 27910857
Front Immunol. 2022 Mar 03;13:844401
pubmed: 35309293
Adv Nutr. 2018 Jul 1;9(4):388-403
pubmed: 30032224

Auteurs

Paola Gualtieri (P)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Rossella Cianci (R)

Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy.

Giulia Frank (G)

School of Specialization in Food Science, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
PhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Erica Pizzocaro (E)

School of Specialization in Food Science, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Gemma Lou De Santis (GL)

PhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Silvia Giannattasio (S)

School of Specialization in Food Science, University of Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Giuseppe Merra (G)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Giovanni Butturini (G)

Division of Hepato-Bilio-Pancreatic Surgery, P. Pederzoli Hospital, Via Monte Baldo 24, 37019 Peschiera del Garda, Italy.

Antonino De Lorenzo (A)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Laura Di Renzo (L)

Section of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH